Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04586816 · ClinicalTrials.gov registry record · NA
Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging
A NA study of Photoaging and Hyperpigmentation, sponsored by Integrative Skin Science and Research.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04586816: Completed NA study of Photoaging and Hyperpigmentation, sponsored by Integrative Skin Science and Research.
NCT04586816 is a NA study of Photoaging and Hyperpigmentation that has completed, run by Integrative Skin Science and Research. The registered enrollment target is 19 participants, below the 31-participant average among 14 other Photoaging trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04586816, a NA study of Photoaging and Hyperpigmentation, has completed, sponsored by Integrative Skin Science and Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
Recent research has reported that the maple leaf extract exhibits anti-aging effects by inhibiting elastase activity, thereby preventing the breakdown of elastin and interfering with the formation of wrinkles. Red maple leaf extract contains phenolic compounds known as glucitol-core-containing gallotannins (GCGs) which help reduce the appearance of wrinkles and may decrease skin inflammation, dark spots and pigmentation. The objective of this study is to examine the effects of topical Maplifa on the cosmetic appearance of facial lines, redness and skin tone.
Primary Outcome
Assessment of pigmentation based on melanin measurement on SkinColorCatch (arbitrary units set by technology)
Conditions Studied
Interventions
- COMBINATION_PRODUCT 1% red maple leaf extract in cream base
- COMBINATION_PRODUCT 5% red maple leaf extract
- COMBINATION_PRODUCT vehicle
Study Locations (1)
California
- Integrative Skin Science and Research - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-09-10 |
| Est. Completion | 2020-01-15 |
| Phase | NA |
What the finished NCT04586816 record still lists
NCT04586816 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 31-participant average among 14 other Photoaging trials with a reported enrollment target (39% lower).
The record links to 3 conditions, with Photoaging appearing as the primary indexed condition, and to 3 interventions - of which 1% red maple leaf extract in cream base is the first listed.
NCT04586816 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04586816 about?
NCT04586816 is a clinical study titled "Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging". Recent research has reported that the maple leaf extract exhibits anti-aging effects by inhibiting elastase activity, thereby preventing the breakdown of elastin and interfering with the formation of wrinkles. Red maple leaf extract contains phenolic compounds known as glucitol-core-containing gallo...
What is the current status of trial NCT04586816?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2019-09-10. Estimated completion is 2020-01-15.
What conditions does trial NCT04586816 study?
This clinical trial studies the following conditions: Photoaging, Hyperpigmentation, Rhytides.
What interventions are being tested in trial NCT04586816?
The interventions under investigation include: 1% red maple leaf extract in cream base (COMBINATION_PRODUCT), 5% red maple leaf extract (COMBINATION_PRODUCT), vehicle (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04586816?
This trial is sponsored by Integrative Skin Science and Research, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04586816 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Photoaging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04586816's enrollment target sits among peer trials
19 13th of 14 higher than 2 of 14 other Photoaging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Photoaging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin
RECRUITING · NA
-
Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies
ACTIVE NOT RECRUITING · NA
-
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Radiofrequency Microneedling for Facial Rejuvenation
COMPLETED · NA
-
Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers
COMPLETED · NA
-
Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment
COMPLETED · NA
-
A Clinical Study to Evaluate Efficacy and Safety of a Cosmetic Product in the Treatment of Facial Lines
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI